Fortress Bio gains on FDA approval of copper replacement therapy
Source: SeekingAlpha
2026-01-13 08:36:34 ET
More on Fortress Biotech
- Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Fortress Biotech
- Historical earnings data for Fortress Biotech
- Financial information for Fortress Biotech
Read the full article on Seeking Alpha
For further details see:
Fortress Bio gains on FDA approval of copper replacement therapy
Fortress Biotech Inc.
NASDAQ: FBIO
FBIO Trading
1.34% G/L:
$3.40 Last:
161,039 Volume:
$3.42 Open:
FBIO Latest News
February 23, 2026 03:52:06 pm
Biotech & Obesity Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger
February 23, 2026 09:24:14 am
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 23, 2026 08:30:00 am
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 23, 2026 08:00:00 am
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
FBIO Stock Data
$117,376,746
22,810,953
3.95%
17
N/A
Biotechnology & Life Sciences
Healthcare
US
Bay Harbor Islands
